concentrix corp - CNXC
CNXC
Close Chg Chg %
43.88 -0.99 -2.26%
Closed Market
42.89
-0.99 (2.26%)
Volume: 626.43K
Last Updated:
Jan 7, 2026, 4:00 PM EDT
Company Overview: concentrix corp - CNXC
CNXC Key Data
| Open $43.87 | Day Range 42.79 - 44.07 |
| 52 Week Range 31.63 - 66.00 | Market Cap $2.73B |
| Shares Outstanding 62.26M | Public Float 43.53M |
| Beta 0.48 | Rev. Per Employee N/A |
| P/E Ratio 9.01 | EPS $4.74 |
| Yield 318.54% | Dividend $0.36 |
| EX-DIVIDEND DATE Oct 24, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 887.52K |
CNXC Performance
| 1 Week | 5.53% | ||
| 1 Month | 16.67% | ||
| 3 Months | -2.01% | ||
| 1 Year | -4.09% | ||
| 5 Years | -60.06% |
CNXC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About concentrix corp - CNXC
Concentrix Corp. engages in the provision of customer experience solutions and technology. The company was founded in 1973 and is headquartered in Newark, CA.
CNXC At a Glance
Concentrix Corp.
39899 Balentine Drive
Newark, California 94560
| Phone | 1-800-747-0583 | Revenue | 9.62B | |
| Industry | Information Technology Services | Net Income | 241.71M | |
| Sector | Technology Services | 2024 Sales Growth | 35.202% | |
| Fiscal Year-end | 11 / 2025 | Employees | 450,000 | |
| View SEC Filings |
CNXC Valuation
| P/E Current | 9.011 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 12.101 |
| Price to Sales Ratio | 0.304 |
| Price to Book Ratio | 0.715 |
| Price to Cash Flow Ratio | 4.38 |
| Enterprise Value to EBITDA | 5.528 |
| Enterprise Value to Sales | 0.841 |
| Total Debt to Enterprise Value | 0.692 |
CNXC Efficiency
| Revenue/Employee | 21,375.333 |
| Income Per Employee | 537.14 |
| Receivables Turnover | 4.992 |
| Total Asset Turnover | 0.786 |
CNXC Liquidity
| Current Ratio | 1.424 |
| Quick Ratio | 1.424 |
| Cash Ratio | 0.215 |
CNXC Profitability
| Gross Margin | 28.559 |
| Operating Margin | 7.881 |
| Pretax Margin | 3.111 |
| Net Margin | 2.513 |
| Return on Assets | 1.975 |
| Return on Equity | 5.908 |
| Return on Total Capital | 2.508 |
| Return on Invested Capital | 2.53 |
CNXC Capital Structure
| Total Debt to Total Equity | 138.558 |
| Total Debt to Total Capital | 58.082 |
| Total Debt to Total Assets | 46.678 |
| Long-Term Debt to Equity | 132.656 |
| Long-Term Debt to Total Capital | 55.607 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Concentrix Corp - CNXC
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 5.59B | 6.32B | 7.11B | 9.62B | |
Sales Growth
| +18.38% | +13.20% | +12.49% | +35.20% | |
Cost of Goods Sold (COGS) incl D&A
| 3.92B | 4.35B | 4.91B | 6.87B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 277.18M | 309.54M | 388.30M | 705.85M | |
Depreciation
| 140.24M | 146.86M | 173.46M | 246.92M | |
Amortization of Intangibles
| 136.94M | 162.67M | 214.83M | 458.93M | |
COGS Growth
| +16.68% | +11.05% | +12.94% | +39.92% | |
Gross Income
| 1.67B | 1.98B | 2.20B | 2.75B | |
Gross Income Growth
| +22.57% | +18.23% | +11.51% | +24.68% | |
Gross Profit Margin
| +29.91% | +31.24% | +30.97% | +28.56% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.14B | 1.27B | 1.45B | 1.99B | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 1.14B | 1.27B | 1.45B | 1.99B | |
SGA Growth
| +8.99% | +10.85% | +14.74% | +36.96% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 2.88M | 91.75M | 154.84M | 117.56M | |
EBIT after Unusual Expense
| 526.58M | 618.44M | 596.21M | 640.48M | |
Non Operating Income/Expense
| 52.17M | 56.64M | (12.54M) | (19.38M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 23.05M | 70.08M | 175.45M | 321.83M | |
Interest Expense Growth
| -52.30% | +204.07% | +150.37% | +83.43% | |
Gross Interest Expense
| 23.05M | 70.08M | 175.45M | 321.83M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 555.70M | 605.00M | 408.23M | 299.27M | |
Pretax Income Growth
| +107.43% | +8.87% | -32.52% | -26.69% | |
Pretax Margin
| +9.95% | +9.57% | +5.74% | +3.11% | |
Income Tax
| 150.12M | 169.36M | 94.39M | 48.06M | |
Income Tax - Current - Domestic
| 62.87M | 70.57M | 90.03M | 97.72M | |
Income Tax - Current - Foreign
| 112.98M | 129.61M | 126.07M | 185.58M | |
Income Tax - Deferred - Domestic
| (21.92M) | (31.90M) | (110.22M) | (124.70M) | |
Income Tax - Deferred - Foreign
| (3.81M) | 1.07M | (11.49M) | (110.55M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| (5.79M) | (6.63M) | (6.00M) | (9.50M) | |
Consolidated Net Income
| 399.79M | 429.01M | 307.84M | 241.71M | |
Minority Interest Expense
| - | - | - | 591.00K | - |
Net Income
| 399.79M | 428.42M | 307.84M | 241.71M | |
Net Income Growth
| +142.58% | +7.16% | -28.14% | -21.48% | |
Net Margin Growth
| +7.16% | +6.77% | +4.33% | +2.51% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 399.79M | 428.42M | 307.84M | 241.71M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 399.79M | 428.42M | 307.84M | 241.71M | |
EPS (Basic)
| 7.7849 | 8.3426 | 5.7218 | 3.72 | |
EPS (Basic) Growth
| +143.74% | +7.16% | -31.41% | -34.99% | |
Basic Shares Outstanding
| 51.35M | 51.35M | 53.80M | 64.98M | |
EPS (Diluted)
| 7.7022 | 8.2811 | 5.7001 | 3.7146 | |
EPS (Diluted) Growth
| +141.15% | +7.52% | -31.17% | -34.83% | |
Diluted Shares Outstanding
| 51.91M | 51.74M | 54.01M | 65.07M | |
EBITDA
| 806.63M | 1.02B | 1.14B | 1.46B | |
EBITDA Growth
| +36.16% | +26.42% | +11.73% | +28.49% | |
EBITDA Margin
| +14.44% | +16.12% | +16.01% | +15.22% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 64.80 | |
| Number of Ratings | 6 | Current Quarters Estimate | 2.897 | |
| FY Report Date | 02 / 2026 | Current Year's Estimate | 12.253 | |
| Last Quarter’s Earnings | 2.905 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 11.373 | Next Fiscal Year Estimate | 13.976 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 5 | 2 |
| Mean Estimate | 2.90 | 2.95 | 12.25 | 13.98 |
| High Estimates | 3.01 | 2.96 | 13.04 | 14.03 |
| Low Estimate | 2.75 | 2.94 | 11.93 | 13.92 |
| Coefficient of Variance | 4.60 | 0.39 | 3.71 | 0.57 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 2 | 2 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Concentrix Corp - CNXC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Concentrix Corp - CNXC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 4, 2025 | Christopher A. Caldwell President and CEO; Director | 280,586 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $36.52 per share | 10,247,000.72 |
| Dec 3, 2025 | Cormac Twomey EVP, Global Ops & Delivery | 35,130 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $35.5 per share | 1,247,115.00 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 292,360 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $50.08 per share | 14,641,388.80 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 280,721 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.19 per share | 13,527,944.99 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 292,588 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $49.46 per share | 14,471,402.48 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 299,042 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.24 per share | 14,425,786.08 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 9,499 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.21 per share | 457,946.79 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 16,675 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $49.42 per share | 824,078.50 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 23,568 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.3 per share | 1,138,334.40 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 1,144,350 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.2 per share | 55,157,670.00 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 1,155,862 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $49.45 per share | 57,157,375.90 |
| Apr 18, 2025 | Olivier Fabrice Duha Director | 1,162,570 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.25 per share | 56,094,002.50 |
| Mar 28, 2025 | Ann F. Vezina Director | 11,947 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 28, 2025 | Kathryn V. Marinello Director | 10,003 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 28, 2025 | Nicolas Joseph Michel Gheysens Director | 7,826 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 28, 2025 | Kathryn J. Hayley Director | 10,011 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 28, 2025 | Jennifer Deason Director | 10,003 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 28, 2025 | Te Chien Chou Director | 306 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 28, 2025 | LaVerne H. Council Director | 10,003 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 28, 2025 | Dennis J. Polk Director | 21,223 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |